Drug Profile
SRD 174
Alternative Names: SRD-174Latest Information Update: 22 Jul 2015
Price :
$50
*
At a glance
- Originator Serentis
- Class Antipruritics
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Pruritus
Most Recent Events
- 22 Jul 2015 Discontinued - Phase-II for Pruritus in USA prior to July 2015 (Topical)
- 01 Jan 2009 Phase-II clinical trials in Pruritus in USA (Topical)